The merger and acquisition merry-go-round is whirling again but Sorrento Therapeutics Inc. is not jumping on yet, having confirmed it has rejected an unsolicited buyout proposal from two biopharmaceutical companies.
Sorrento Resists M&A Frenzy
US Biotech Rejects Unsolicited Bid
Two pharma companies have made an offer for Sorrento Therapeutics that could triple the pain management and immune-oncology specialist's value but the San Diego-based group is holding firm.
More from Deals
• By
Both vexed by bankruptcies and opioid litigation, Endo and Mallinckrodt will merge in a deal valued at $6.7bn. The new company will spin out its generics and sterile injectable business.
• By
Evaluate Pharma’s top 10 list of unpartnered mid-stage obesity assets shows that few credible challengers to Novo’s Wegovy and Lilly’s Zepbound remain available.
• By
CEO Adam Steensberg has led a major change in fortunes for the Danish biotech since March 2022.
• By
With two major deals since just the beginning of the year in Japan, private equity groups appear to be ramping up their presence in the country's biopharma sector, amid ongoing activity across the wider APAC region.
More from Business
• By
Ono agreed to pay $280m up front for global rights to Ionis’s Phase II polycythemia vera candidate, which analysts say was de-risked by recent data reported for other PV drugs.
• By
Scrip senior writer Joseph Haas discusses recent industry merger-and-acquisition activity with attorneys Jessica Bisignano and Gabrielle Witt of Hogan Lovells.
• By
The Swiss giant has inked a deal potentially worth $5.30bn with Zealand to access the Danish biotech's long-acting amylin analog petrelintide.